Pei-Jin Bai

Longitudinal kidney outcomes and safety after finerenone initiation in patients with non-diabetic chronic kidney disease: a single-center retrospective cohort study

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has demonstrated renoprotective effects in randomized controlled trials. However, real-world evidence, particularly in heterogeneous and non-diabetic chronic kidney disease (CKD) populations, remains limited. This was a single-center, retrosp...